Fortress BiotechFBIO.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, Fortress Biotech (FBIO.O) trades at a P/E of 0.60x, P/B of 0.38x, P/S of 0.91x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 3rd percentile over the trailing 10Y window (vs. 3rd percentile over 3Y); P/B sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 25th percentile over the trailing 10Y window (vs. 52nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 1st percentile within its industry and the 1st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.42%, ranking at the 100th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 3.2 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Fortress Biotech operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: FBIO · FBIO
Want the full picture on whether Fortress Biotech (FBIO.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 0.60 | ||||||
| P/B (MRQ) | 0.38 | ||||||
| P/S (TTM) | 0.91 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.42% |